跳转至内容
Merck
  • Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.

Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.

Gastroenterology (2014-03-04)
Yijin Wang, Xinying Zhou, Yannick Debing, Kan Chen, Luc J W Van Der Laan, Johan Neyts, Harry L A Janssen, Herold J Metselaar, Maikel P Peppelenbosch, Qiuwei Pan
摘要

Many recipients of organ transplants develop chronic hepatitis, due to infection with the hepatitis E virus (HEV). Although chronic HEV infection is generally associated with immunosuppressive therapies, little is known about how different immunosuppressants affect HEV infection. A subgenomic HEV replication model, in which expression of a luciferase reporter gene is measured, and a full-length infection model were used. We studied the effects of different immunosuppressants, including steroids, calcineurin inhibitors (tacrolimus [FK506] and cyclosporin A), and mycophenolic acid (MPA, an inhibitor of inosine monophosphate dehydrogenase) on HEV replication in human hepatoma cell line Huh7. Expression of cyclophilins A and B (the targets of cyclosporin A) were knocked down using small hairpin RNAs. Steroids had no significant effect on HEV replication. Cyclosporin A promoted replication of HEV in the subgenomic and infectious models. Knockdown of cyclophilin A and B increased levels of HEV genomic RNA by 4.0- ± 0.6-fold and 7.2- ± 1.9-fold, respectively (n = 6; P < .05). A high dose of FK506 promoted infection of liver cells with HEV. In contrast, MPA inhibited HEV replication. Incubation of cells with guanosine blocked the antiviral activity of MPA, indicating that the antiviral effects of this drug involve nucleotide depletion. The combination of MPA and ribavirin had a greater ability to inhibit HEV replication than MPA or ribavirin alone. Cyclophilins A and B inhibit replication of HEV; this might explain the ability of cyclosporin A to promote HEV infection. On the other hand, the immunosuppressant MPA inhibits HEV replication. These findings should be considered when physicians select immunosuppressive therapies for recipients of organ transplants who are infected with HEV.

材料
货号
品牌
产品描述

Sigma-Aldrich
地塞米松, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
地塞米松, ≥98% (HPLC), powder
USP
他克莫司, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
钾, chunks (in mineral oil), 98% trace metals basis
Sigma-Aldrich
泼尼松龙, ≥99%
Sigma-Aldrich
氢化钾, 30 wt % dispersion in mineral oil
Sigma-Aldrich
地塞米松, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
地塞米松, United States Pharmacopeia (USP) Reference Standard
Supelco
地塞米松, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
FK-506 一水合物, ≥98% (HPLC)
Sigma-Aldrich
氢化钾, in paraffin
Supelco
泼尼松龙, Pharmaceutical Secondary Standard; Certified Reference Material
USP
泼尼松龙, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
地塞米松, meets USP testing specifications
Sigma-Aldrich
地塞米松, tested according to Ph. Eur.
泼尼松龙, European Pharmacopoeia (EP) Reference Standard
Supelco
地塞米松, VETRANAL®, analytical standard
Supelco
泼尼松龙, VETRANAL®, analytical standard
地塞米松, European Pharmacopoeia (EP) Reference Standard
地塞米松, European Pharmacopoeia (EP) Reference Standard
峰鉴别用泼尼松龙, European Pharmacopoeia (EP) Reference Standard
泼尼松龙, British Pharmacopoeia (BP) Assay Standard
地塞米松, British Pharmacopoeia (BP) Assay Standard
泼尼松龙, European Pharmacopoeia (EP) Reference Standard
地塞米松, European Pharmacopoeia (EP) Reference Standard